Abstract:Aim: This work aims to understand potential inhibitory structural requirements and identify lead compounds for non-small cell lung cancer through 3D-QSAR pharmacophore-based virtual screening, molecular docking, CoMSIA and CoMFA QSAR modelling. Materials and Methods: QSAR pharmacophore models were developed by HypoGen Module and validated by test data set, Fischer's randomization and Guner-Henry equation. The well-validated pharmacophore model was employed to perform virtual screening to identify potent hits from ZINC database. The retrieved hits were subsequently subjected to filtering using ADMET descriptors and Lipinski's Rule of Five. CoMSIA and CoMFA were then utilized to produce QSAR models on phenylpyrimidine derivatives also. Results: Validations on 3D-QSAR pharmacophore model indicate that the enrichment factor is 6.34, GH is 0.517 and a correlation coefficient is 0.83, implying its highly predictive ability. Top three hits: ZINC29356266, ZINC06589615, and ZINC03375633 were identified as promising potent inhibitory candidates with IC50 value of about 0.54 pM and fitness value of about 59.4. Interestingly, the top three hits indicate dual inhibitory activity targeting EGFR and PD-L1 from structure-based docking. Two developed QSAR models from CoMSIA and CoMFA modelling indicate a potential predictive ability (q(2)=0.67, and 0.71 respectively). The designed compound C indicates a more potential (dual) inhibitory activity (pIC50=7.39) targeting EGFR (fitness=59.78) and CTLA-4 (fitness =47.90). Conclusion: Validations indicate that the developed 3D-QSAR pharmacophore model is highly predictive. Top three hits were identified as promising potent inhibitory candidates and indicated dual inhibitory activity targeting EGFR and PD-L1. The designed compound C indicates a more potential (dual) inhibitory activity targeting EGFR and CTLA-4. These important 3D-QSAR and molecular docking bioinformatics results achieved from this work should be valuable in designing more promising potent inhibitory candidates and developing novel lead compounds against advanced NSCLC in future.

Integration of 3D-QSAR, Molecular Docking, and Machine Learning Techniques for Rational Design of Nicotinamide-Based SIRT2 Inhibitors

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

Research and study of 2-((4,6 dimethyl pyrimidine-2-yle) thio)-N-phenyl acetamide derivatives as inhibitors of sirtuin 2 protein for the treatment of cancer using QSAR, molecular docking and molecular dynamic simulation

Molecular Modeling, Chemical Synthesis and Biological Assays

Targeting Sirtuin 1 for therapeutic potential: Drug repurposing approach integrating docking and molecular dynamics simulations

Computational Design and Optimization of Peptide Inhibitors for SIRT2

Discovery of 5-(Substituted Phenyl)-2-aryl Benzimidazole Derivatives as SIRT1 Activators: Their Design, in silico Studies, Synthesis, and in vitro Evaluation

Exploring and Designing Potential Inhibitors of SIRT2 in Natural Products by Artificial Intelligence (AI) and Molecular Dynamics Methods

In silico screening of small molecule modulators and their binding studies against human sirtuin-6 protein

Identifying Potential Dual Inhibitory Candidates for Non-Small Cell Lung Cancer Through Molecular Docking, 3D-QSAR Pharmacophore-based Virtual Screening, Comparative Molecular Field and Similarity Indices Analysis Modeling

In silico drug discovery of SIRT2 inhibitors from natural source as anticancer agents

Identification of novel human nicotinamide N-methyltransferase inhibitors: a structure-based pharmacophore modeling and molecular dynamics approach

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Symmetrical 2,7‐disubstituted 9H‐fluoren‐9‐one as a novel and promising scaffold for selective targeting of SIRT2

2D-QSAR modeling, drug-likeness studies, ADMET prediction, and molecular docking for anti-lung cancer activity of 3-substituted-5-(phenylamino) indolone derivatives

In silico insights into design of novel VEGFR-2 inhibitors: SMILES-based QSAR modelling, and docking studies on substituted benzo-fused heteronuclear derivatives

Mechanism of Inhibition of the Human Sirtuin Enzyme SIRT3 by Nicotinamide: Computational and Experimental Studies

Identification of small molecular inhibitors of SIRT3 by computational and biochemical approaches a potential target of breast cancer

Pharmacophore-guided in-silico discovery of SIRT1 inhibitors for targeted cancer therapy

Structure–Activity Relationship for Small Molecule Inhibitors of Nicotinamide N -Methyltransferase

Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects